fect intraspinal pressure. In the future, predictable swelling properties of hydrogels may be leveraged to control intraspinal pressure after injury. Here, we review the physiology of SCI, with special attention to the current clinical and experimental literature, underscoring the importance of controlling intraspinal pressure after SCI. We then discuss how hydrogel fabrication, injection, and swelling can impact intraspinal pressure in the context of developing injectable biomaterials for SCI treatment. 
Introduction
Spinal cord injury (SCI) currently affects 270,000 Americans with roughly 15,000 new injuries each year [Singh et al., 2014] resulting in partial or complete loss of neurological function at and below the level of injury. In addition to the loss of muscle innervation and function, SCI compromises immune and endocrine function, necessitating clinical management as a chronic disease rather than a purely physical disability. Unfortunately, SCI is incurable and current treatments -which include antiinflammatory steroids, spinal decompression of bony impingements, and physical rehabilitation -only marginally improve neurological recovery.
Biomaterial-based strategies have generated substantial excitement for SCI treatment (427 citations can be retrieved in PubMed using the keywords 'biomaterials' and 'spinal cord injury'), but implantable materials are less attractive for clinical translation than injectable systems because they require the removal of potentially spared tissue. This is in part due to the irregularly sized defect that occurs after injury to the spinal cord. Researchers are therefore developing injectable biomaterials that can be delivered into, and integrate with, the injured tissue to mediate repair. Biomaterials can be custom designed to reduce inflammation, aid in resealing of the blood-brain barrier and/or promote the regeneration of spinal cord tissue through incorporation of bioresponsive elements such as cell adhesion peptides. In addition, biomaterials can be used as localized delivery vehicles for biological therapeutics, including genes, proteins, drugs and even stem cells. The ability to incorporate multiple factors within similar delivery vehicles provides potential for complex combinatorial therapies to address multiple barriers to repair that exist after SCI. Localized delivery is particularly important for applications in the spinal cord, as systemically delivered therapeutics are typically inefficient at crossing the blood-brain barrier and/or glial scar to reach tissue in the central nervous system (CNS). Readers are referred to the following excellent articles for more general reviews of biomaterial-based strategies for SCI treatment: Potter et al. [2008] ; Cui et al. [2010] ; Rubert Perez et al. [2015] .
Here, we focus on recent developments in injectable hydrogels and specifically how these materials may affect secondary injury by influencing local tissue swelling. Although initial studies have demonstrated promise, very little is known about how injectable materials contribute to the swelling and pressure at the injection site, and integrate with the native tissue. Despite these unknowns, there are common standards for injection volume and rate that are thought to cause minimal damage to the spinal cord, at least in experimental animal models [Baumann et al., 2009; Patel et al., 2010; Singh et al., 2014] . We review recent developments in injectable materials for SCI with a focus on the importance of maintaining physiological tissue pressure. Along these lines, special attention is paid to hydrogel swelling and mesh size as we discuss individual biomaterials. In the following section, we first examine current knowledge of intraspinal pressure build up after traumatic SCI ( fig. 1 ) and its potential contribution to the development of secondary damage after SCI.
Pressure-Induced Damage to the Spinal Cord after the Primary Injury
The spinal cord is rarely severed by the initial traumatic insult, and experimental studies demonstrate that primary gross tissue damage is remarkably limited in most cases, where although hemorrhage is seen in the central gray matter, the surrounding white matter is morphologically intact within the first hour following injury [Balentine, 1978; Noble and Wrathall, 1989] . However, the primary insult is followed by a cascade of events known as secondary injury, which includes the release of free radicals and excitatory neurotransmitters, inflammation, edema, and ischemia that results in the widespread death of cells that survived the primary injury. Limiting secondary damage to the spinal cord tissue continues to be an active area of research for improving functional outcomes in patients with SCI. Currently, clinical treatments for acute SCI, including steroids [Kuchner et al., 2000] and hypothermia [Romodanov et al., 1979; Janssen and Hansebout, 1989; Alkabie and Boileau, 2016] , seek to prevent or mitigate secondary injury by reducing inflammation and, indirectly, edema. For example, a recent review study reported evidence that localized and systemic hypothermia reduces many of the events associated with secondary damage after SCI, such as ischemia, oxidative stress, apoptosis, inflammation, and edema [Alkabie and Boileau, 2016] .
It has long been recognized that immediately after injury to the brain or spinal cord, there is a significant amount of swelling within the local tissue. Indeed, for patients with traumatic brain injury (TBI) there are specific clinical guidelines for intensive monitoring of brain tissue pressure combined with pharmacological and surgical interventions with the goal of maintaining adequate brain tissue perfusion and oxygenation to minimize secondary injury [Bratton et al., 2007] . This treatment paradigm has resulted in a significant reduction of mortality and morbidity associated with TBI and is attributed to the significant improvements in clinical outcomes for these patients [Marshall et al., 1979; Miller et al., 1981] . A few recent studies have suggested that increases in tissue pressure after SCI are associated with negative functional outcomes Varsos et al., 2015] ( fig. 1 a) , and surgical alleviation of this pressure improves functional outcomes in both experimental animals [Yang et al., 2013] as well as patients . However, currently there are no clear clinical guidelines for monitoring and managing intraspinal pressure after SCI. Experimental data from our lab using a rodent model of SCI in the thoracic cord showed that immediately after a moderate contusive injury there was a significant increase in intraspinal pressure (up to five times the normal intraspinal pressure; 1.8 ± 0.4 mm Hg [ ∼ 240 Pa] vs. 8.9 ± 1.1 mm Hg [ ∼ 1,200 Pa]; fig. 1 b) [Khaing et al., 2016] . In this set of experiments, a highly sensitive micropressure probe (300-μm Milar ® probe) was inserted directly into the spinal cord to obtain an accurate tissue pressure recording at 1 kHz. Hence, as we develop new therapies using injectable biomaterials for implantation into the spinal cord, swelling of these materials in vivo is an important consideration. Edema -abnormalities in the location and amount of water -is associated with many pathological conditions of the CNS, including traumatic SCI, TBI, and stroke [Simard et al., 2012; Kurland et al., 2013] . Edema leads to an increase in local pressure, potentially causing tissue isch- Local intraspinal pressures increase significantly after injury to the spinal cord. a In humans, the injury area within the spinal cord was imaged using a magnetic resonance scan (left image) and the schematic diagram shows different compartments within the spinal cord after injury. Increases in ISP (instraspinal pressure) can be measured using subdural pressure probes to estimate tissue pressure (below). Con = Control; TSCI = traumatic SCI. * * * p < 0.001. Adapted from Werndle et al. [2014] . b An ultrasound image of a rat spinal cord 15 min postinjury detects hemorrhaging at the lesion epicenter. The dotted circle approximates the injury center. In rodents, significant increases in ISP were directly measured using a pressure probe inserted into the lesion epicenter. ISP was measured utilizing a 1 F Millar Mikro-Tip ® pressure probe (tip diameter 330 μm). For insertion of the probe, a small dural defect was produced with a No. 11 surgical blade. ISP was recorded in 6 intact animals to establish a preinjury baseline. In injured animals, the probe was inserted into the spinal cord approximately 4 mm caudal to the injury center. The probe was subsequently advanced rostrally into the injury center. For a total of 7 animals, ISP recordings were performed immediately after injury continuously for 4 h. * * * p < 0.001. Adapted from Khaing et al. [2016] .
emia and eventually cell death [Simard et al., 2012; Kurland et al., 2013] . Aquaporins (AQPs), a family of transmembrane proteins that serve as channels for water, are expressed throughout the brain and spinal cord [Manley et al., 2004; Bradl and Lassmann, 2008; Benfenati and Ferroni, 2010; Hinson et al., 2010; MacAulay and Zeuthen, 2010; Saadoun and Papadopoulos, 2010; Verkman et al., 2011; Brosnan and Raine, 2013; Delgado et al., 2014; Freitas and Guimaraes, 2015] . Anatomically, AQP4 -the most abundant AQP in the spinal cord [Shibuya et al., 2008] -is situated to be a key player in pathological edema. AQP4 is highly expressed in astrocytic end-feet in direct contact with blood vessels [Frigeri et al., 1995; Nielsen et al., 1997b] and osmoregulatory centers of the brain, including the hypothalamic magnocellular nuclei [Jung et al., 1994; Nielsen et al., 1997a] . Hence, AQP biology is likely to be important for maintaining fluid homeostasis in the CNS. Interestingly, several recent reports have found that a decreased AQP4 function correlates with improved functional recovery after TBI [Fukuda et al., 2013; Dardiotis et al., 2014] , and SCI [Kimura et al., 2010; Jing et al., 2014; Sato et al., 2014; Wu et al., 2014; Hu et al., 2015] , suggesting that edema associated with injury to the CNS is likely to be mediated in part by AQP receptors. Despite these discoveries, the cellular mechanisms of swelling-induced damage in the CNS remain elusive.
Design Considerations for Hydrogels Promoting SCI Repair
Several hydrogel properties are considered relevant to their application to SCI treatment, particularly in injectable systems, including the injection method, injection location, mechanical properties of hydrogel materials before and after in situ crosslinking, and hydrogel swelling. One of these is gelation properties that must be compatible with the injection conditions necessary to avoid additional injury to the cord tissue: a syringe capable of delivering small volumes at a controlled rate equipped with a small needle. Specific sizes depend upon the injury model used, with needles as small as 33 G used for rodent studies [Gupta et al., 2006; Sontag et al., 2014; Führmann et al., 2015] , and needles up to as large as 23 G used in human clinical trials [Oraee-Yazdani et al., 2016; Shin et al., 2015] . These requirements dictate that the precursor must be liquid or highly deformable.
For biomaterial applications in vivo, it will be critical to determine the optimal therapeutic volume that may be added into the spinal cord without causing tissue damage.
This threshold for injection volume may depend on the location of the injection and spinal cord tissue blood perfusion in addition to intraspinal tissue pressure. Limiting the local tissue blood perfusion is associated with negative functional outcomes after traumatic SCI [Hall and Wolf, 1987; Alshareef et al., 2014] . Conventionally, it was thought that the anatomy of the spinal column allows for substantial room for tissue swelling, and therefore standard clinical guidelines for examining and maintaining intraspinal pressure after injury do not yet exist. Despite a consistent lack of consideration for relieving increases in tissue pressure after SCI, recent data suggest that in a large population of SCI patients (84%) there is significant intraspinal swelling and increase in pressure after injury that results in negative clinical outcomes [Werndle et al., 2014] . Therefore, the swelling of biomaterials exogenously applied to the spinal cord is likely to be a key determinant of therapeutic success.
While it is generally assumed that injection of large volumes into the spinal cord will cause damage to the tissue, there is minimal research to quantitatively determine the range of acceptable injection volumes. There are, however, common accepted standards for volumes of 1-2 μl of cell solutions or hydrogels injected per site into the mouse cord [Shin et al., 2015; Oraee-Yazdani et al., 2016] or 5-10 μl in the rat spinal cord [Yang et al., 2009a; Lu et al., 2012; Song et al., 2012; Führmann et al., 2015] . Complicating the situation, the acceptable range for injection volumes is likely to be specific to the unique swelling properties of each hydrogel formulation. The pressure exerted by a highly swelling hydrogel can potentially exacerbate the already increased intraspinal pressure after acute SCI, resulting in the loss of tissue perfusion, and can further damage the surrounding soft tissue. However, at this time, we are not aware of any studies in which local tissue pressure is determined after biomaterial application in vivo.
Given the various volumes that different injection sites can accommodate, injection location is an important consideration. Normally, the spinal cord is freely floating within the spinal column, and therefore materials injected into the subdural space are likely to exert less physical compression and be better tolerated. However, this decision will depend on the therapeutic goal of the hydrogel. For instance, as a scaffold for axonal growth and/or cell transplantation, hydrogels may be injected directly into the spinal cord parenchyma (or into the cyst after SCI), while hydrogels designed for drug delivery or osmotic transport to relieve swelling may be more effective when injected into the subarachnoid (also known as 'intrathe-cal') space ( fig. 2 b) . In humans, the cross-sectional area of the spinal cord tissue at the cervical level is about 120 mm 2 at its largest region [Sherman et al., 1990] . The subarachnoid space between the dural and the pial membranes ( fig. 2 ) is approximately 5.5 mm in the cervical spine [Ulbrich et al., 2014] and about 7.6 mm in the thoracic spine [Gellad et al., 1983] . Therefore, there is some room for swelling within human spinal cord before creating a significant increase in tissue pressure. However, in rats, the most commonly used experimental animal model of SCI, the largest area of the spinal cord is only about 28 mm 2 and the subarachnoid space is less than 1 mm. Therefore, there is limited space available for the application of therapeutic materials. Table 1 summarizes recently developed injectable biomaterials that are being tested in preclinical models. Note that the list includes materials that swell up to 50% more than their original volumes. While intraspinal pressure measurements have not directly been recorded after in vivo application and the swelling of hydrogels, we expect that significant swelling within the spinal cord parenchyma will likely be detrimental to the surrounding soft spinal tissue. Although little systematic research has been conducted regarding this issue, there are instances in the clinic where exogenously applied biomaterials have caused negative neurological outcomes (see complications associated with DuraSeal ® below). In future studies, it will be important to determine the effects of swelling on local tissue pressure once in vivo.
As edema is one of the common features after injury to the CNS (both SCI and TBI), and is thought to be associated with negative functional outcomes. It is intriguing to explore the use of hydrogels that can absorb excess liquid locally and potentially restore fluid homeostasis after CNS injury. A recent report by McBride et al. [2014] utilizes an osmotic transport device (OTD) containing hollow fibers -filled with an osmotic agent that will create a chemical potential pressure for water -that are embedded within a highly swelling hydrogel material that can locally draw out excess water from the underlying brain tissue. The authors showed that application of the OTD after TBI reduced brain edema better than craniotomy alone. A limitation of this study is that the authors did not examine the local intracranial pressure after the excess water was reduced using the OTD and whether this resulted in neurological outcomes. For application in the spinal cord, these types of fluid-absorbing (i.e. swelling) hydrogels should only be applied to injection locations (e.g. the intrathecal space instead of directly into the spinal cord) in which the swelling of the material would have limited negative impact on the surrounding tissue.
It is well known that cells sense and respond to their mechanical environment, which regulates a wide range of biological processes. Hydrogels exhibiting elastic moduli within the range of healthy CNS tissues -roughly below 1 kPa by rheological measurements or below 10 kPa by Stiffness was measured either by rheology (G' = storage modulus; G* = shear modulus) or linear compressive modulus (G). Swelling is reported as an increase in mass or volume between the point of gelation and after equilibration in a physiological buffer.
linear compressive measurements -better support neuronal cell survival and a functional phenotype than stiffer substrates [Georges et al., 2006; Leipzig and Shoichet, 2009; Seidlits et al., 2010; Man et al., 2011] . The implantation of hydrogels exhibiting compressive moduli similar to native spinal cord ( ∼ 2-4 kPa) into rodent spinal cords after acute injury has been reported to reduce the number of inflammatory cells and glial scar deposition [Bakshi et al., 2004; Khaing et al., 2011] . In vitro studies have shown that hydrogel scaffold mechanics greatly influence neurite outgrowth -a necessary process for spinal cord regeneration -where maximum neurite migration occurs on the softest substrate evaluated (typical compressive moduli of 0.5-5 kPa) [Balgude et al., 2001; Flanagan et al., 2002; Willits and Skornia, 2004; Gunn et al., 2005; Georges et al., 2006; Lampe et al., 2010; Man et al., 2011] . It is important to note that in the majority of studies reporting effects of mechanical cues on CNS biology, biomaterial mechanics and swelling were not decoupled. Beyond the elastic modulus, the viscous properties of injectable hydrogels should be considered, as they will determine the ease of injection through a small-gauge needle and the extent that hydrogel precursors diffuse from the injection site prior to gelation. Shear-thinning materials, like hyaluronic acid (HA), are particularly appealing for their ability to relax in response to increased applied pressures, acting to protect encapsulated therapeutic agents from shear-induced damage [Aguado et al., 2011] and perhaps minimize pressures exerted during swelling after crosslinking in situ.
For in vivo delivery to the spinal cord, injectable hydrogels must be designed to balance the requirement for soft materials that mimic native tissue with that for controlled swelling. Studies in rodents have suggested that providing physical support via biomaterials in the acute phase after SCI may prevent cyst formation and reduce glial scar deposition [Prang et al., 2006; Yang et al., 2009b; Tuinstra et al., 2013b; Pawar et al., 2015b] . In the case of hydrogel biomaterials, this support may be provided by the mechanical strength or swelling pressure exerted on the surrounding tissue to hold the implant in position and form a tight interface with the host tissue. Given these requirements, independent control of hydrogel swelling pressure and mechanics will be necessary to provide both good apposition to host tissue and appropriate biological cues for CNS cell function, respectively. Although a few methods have been developed recently that at least partially decouple scaffold mechanics, swelling and mesh size [Jia et al., 2006; Lampe et al., 2010; Browning et al., 2011; Bearat et al., 2012; Griffin et al., 2015; Schweller and West, 2015] , further advancements to expand the range over which these properties can be independently controlled will likely be required for applications in CNS tissues, which are very soft yet highly sensitive to changes in tissue pressure.
Hydrogel Swelling and Clinical Considerations
The swelling properties of hydrogels have not received sufficient attention within the context of biomaterialbased treatment strategies for SCI. Swelling properties can vary significantly based on the hydrogel composition and crosslinking technique. Highly hydrophilic polymers, especially those with charged backbones, can swell to more than twice their size after formation [e.g. polyethylene glycol (PEG) and HA hydrogels], whereas protein-based polymers (e.g. collagen and fibrin hydrogels) tend to swell minimally ( fig. 3 a) . Indeed, when we examined the pressure exerted during gel swelling, 2% PEG, 1% HA-PEG and collagen-laminin-HA hydrogels showed physiologically compatible pressures (<1,000 Pa; fig. 3 b) . As stated above, normal spinal cord tissue pressure is ∼ 240 Pa, but approached ∼ 1,200 Pa after SCI. Therefore, swelling pressures exerted by both 2% HA-PEG (>2,000 Pa) and 4% PEG gels (>10,000 Pa) are not likely to be optimal for in vivo transplantations and/or injections. While most researchers use volumetric or mass swelling ratios (as in fig. 3 a) to assess whether the swelling of an injectable material is appropriate for use in vivo, our data show that this measure is not necessarily quantitatively predictive of pressure exerted during swelling ( fig. 3 b) . For example, while 1% HA-PEG and 2% PEG hydrogels have similar equilibrium swelling ratios ( ∼ 30% increase in mass), the peak pressure exerted by 2% PEG hydrogels is approximately double that for 1% HA-PEG hydrogels. In addition, hydrogels containing less than 1% HA, including collagen-HA-laminin and 1% HA-PEG hydrogels, show an initial increase to peak pressures during the first several minutes of swelling and then rapidly decrease. As HA is a polymer with considerable shear-thinning properties, we posit that HA-containing hydrogels may be able to relax after initial swelling, thus reducing pressures exerted by the material over time. Therefore, direct measurements of local spinal tissue pressure before and after hydrogel application in vivo are needed to confirm these ex vivo observations. Some researchers have examined the swelling properties of hydrogels in experimental settings (in preclinical models) for applications within the CNS [Baumann et Bjugstad et al., 2010; Kubinova et al., 2011; Neuman et al., 2012] . Indeed, Bjugstad et al. [2010] implanted a strand of photocrosslinked PEG gel that was preformed, but not preswollen, into the ventral midbrain. They found that the application of this hydrogel into the CNS parenchyma resulted in: (1) a tissue 'vacancy' increase (5-20% likely due to swelling) after hydrogel application; (2) in vitro swelling behavior of the gels that did not match that of the ones implanted in vivo, and finally (3) the defect size continued to get smaller overtime in rapidly degrading gels, presumably due to sufficient infiltration of host cells as the hydrogel degraded. Interestingly, the authors also found that the magnitude of the acute microglia response and the long-term astrocytic scarring response were attenuated when the PEG-based hydrogels were used compared to control animals .
In future studies, it will be important to determine the acceptable swelling range for implanted material within the CNS tissue, and to determine the effects of hydrogel swelling on host tissue response. DuraSeal ® , an FDA-approved injectable hydrogel formulation currently in clinical use to help seal the dura, is an example of a biomaterial with swelling properties that have limited its utility. The contraindications for this product suggest that this hydrogel may swell to up to 50% of its original size in any dimension -common for hydrogels in development for clinical use ( table 1 ) Hydrogel swelling can produce detectable forces. a Samples were swollen uniaxially in buffer and the resulting swelling forces were measured using a fixed probe on an Instron 5564 linear compressive tester. The formulations were as follows in PBS: 4% PEG [20 mg/ml PEG-vinyl sulfone (VS) and PEG-thiol (SH)], 2% PEG (10 mg/ml PEG-VS and PEG-SH), 2% HA (20 mg/ml HA-SH and PEG-VS), 1% HA (10 mg/ml HA-SH and PEG-VS), HA-laminin (LN)-collagen (Col), 3 mg/ml each. b Hydrogels were swollen in buffer until equilibrium was reached. The hydrogel mass was measured at the time of gelation and after swelling. The swelling percentage was calculated as the change from initial mass after equilibration in physiological buffer. The formulations were as follows in PBS: 1% HA (10 mg/ml HA-SH and PEG-VS), 2% HA (20 mg/ml HA-SH and PEG-VS), collagen (3 mg/ml), fibrin (8 mg/ml), HA-LN-Col (3 mg/ml each), 4% PEG (20 mg/ml PEG-VS and PEG-SH), 2% PEG (10 mg/ml PEG-VS and PEG-SH). All measurements were acquired at room temperature. [Mulder et al., 2009; Neuman et al., 2012; Lee et al., 2013] . Swelling of the DuraSeal ® hydrogels at the site of application had adverse effects in the higher cervical level where there is less space between the bony vertebra and the spinal cord parenchyma [Lee et al., 2013] , as well as in the cauda equina where there is a relatively larger space between the vertebra and the spinal cord [Mulder et al., 2009; Neuman et al., 2012] . It is also important to consider that the application of hydrogel material within the subdural space (as mentioned above, the spinal cord is freely floating within the spinal column) can migrate away from the site of application, so that the adverse effects may be detected at distant sites [Mulder et al., 2009] . In light of substantial data on the importance of maintaining normal intraspinal pressure -combined with these clinical failures associated with hydrogel swelling -it is imperative that swelling is one of the key features to be examined extensively before testing biomaterial applications in vivo, and also once applied in vivo. In the following sections, we will discuss a number of recently developed hydrogels for applications in the CNS with a focus on swelling properties.
Fabrication Strategies for Injectable Hydrogels
Although some 'shape-memory' or 'self-healing' injectable materials have been developed [Bencherif et al., 2012; Koshy et al., 2014; Hsieh et al., 2015] , fabrication strategies are typically chosen so that gelation occurs in the aqueous CNS environment only after injection and penetration throughout the tissue defect, creating an intimate interface between injected materials and the healthy tissue that facilitates cell migration and regeneration. Commonly used conditions to trigger in situ crosslinking include: (1) exposure to a specific wavelength of light [Piantino et al., 2006; Khaing et al., 2011] , temperature [Gupta et al., 2006; Bearat et al., 2012] , or pH [Prang et al., 2006; Pawar et al., 2015b] , and (2) combining two separate components that spontaneously react upon mixing [Johnson et al., 2010a; Nimmo et al., 2011; Liang et al., 2013; Führmann et al., 2015; Kim et al., 2016] . In situ crosslinking of hydrogels in response to various triggers has been achieved by covalent chemistries (e.g. chaingrowth polymerization, step-growth polymerization, Michael addition, Diels-Alder cycloaddition, enzymatic) [Johnson et al., 2010a; Liang et al., 2013; Führmann et al., 2015] , physical means (e.g. electrostatic and/or hydrophobic interactions) [Gupta et al., 2006; Piantino et al., 2006] or a combination of both [Bearat et al., 2012; Pakulska et al., 2015] . Many of these strategies have been used to form hydrogels in situ within the spinal cord with good biocompatibility ( table 1 ) .
In all of these strategies, common methods are used to control the maximum degree of hydrogel swelling in situ ( fig. 4 ) . Increasing the macromer concentration and/or crosslinking density will decrease swelling, but at the expense of increased mechanical strength and decreased permeability, which may have adverse effects. Similarly, the addition of hydrophilic and/or electrostatically charged moieties will increase water uptake at the expense of increased network permeability and possible effects on hydrogel mechanics. Shape-memory [Koshy et al., 2014] and microparticle-based [Jia et al., 2006; Griffin et al., 2015] hydrogels have the important advantage of being preswollen prior to in vivo delivery. However, at least in the case of shape-memory materials, reversion to a larger size after injection may cause tissue damage similar to pressures exerted during in situ swelling. Alternatively, maximal swelling may be advantageous for hydrogels applied to the subdural space, where they could act to siphon off the excess fluid in the parenchyma that accumulates after SCI to prevent secondary damage, as recently demonstrated in TBI [McBride et al., 2014] . In either case, better strategies to improve control over hydrogel swelling by decoupling this property from other network properties are needed [Browning et al., 2011; Bearat et al., 2012; Shih and Lin, 2012] .
Noncovalent gelation strategies include materials designed to undergo a phase transition in physiological conditions (often temperature or pH induced) such that network formation occurs through the physical association of macromers through hydrophobic/hydrophilic or electrostatic interactions. Such gelation methods based on phase transition are highly biocompatible as they eliminate the need for nonbiological chemical reagents. For example, thixotropic, HA-methylcellulose (HAMC) composite materials form through phase separation at physiological temperatures -where hydrophobic regions associate to yield physical crosslinks -after injection into the spinal cord ( table 1 ) [Gupta et al., 2006; Tam et al., 2012; Caicco et al., 2013] . These hydrogels have been reported to swell to about 50% of their original mass and in vivo (intraspinal and intrathecal) applications of this type of gel appears to be tolerated, although intraspinal pressures were not measured after material injection. It is interesting to note that the resulting networks are fundamentally more inhomogeneous than step-growth polymerized hydrogels, containing hydrophobic 'pockets' throughout. Other noncovalent crosslinking includes the calcium-mediated crosslinking of alginate hydrogels [Prang et al., 2006; Ansorena et al., 2013; des Rieux et al., 2014; Grulova et al., 2015; Gunther et al., 2015; Pawar et al., 2015b] and self-assembly of amphiphilic polymers [Silva et al., 2004; Tysseling-Mattiace et al., 2008; Song et al., 2012; Yang et al., 2013] , with both types of hydrogels reporting swelling of about 40%. Self-assembled hydrogels are often fabricated from designer polypeptides, which provides a high degree of control over network assembly as each amino acid is user specified.
Photocrosslinking techniques, including chaingrowth and step-growth polymerization, typically involve the addition of an initiator that is activated in response to the crosslinking trigger (e.g. light or heat) and induces covalent bonding between polymer precursors. While chain-growth methods (such as acrylate-mediated crosslinking) have been widely investigated, more recently step-growth polymerization methods have gained popularity based on their ability to create better-defined networks with predictable properties (e.g. swelling, mechanics) [Azagarsamy and Anseth, 2013; Tibbitt et al., 2013] .
Step-growth photopolymerization typically involves 'click' chemistry reagents, such as the norbornene-thiol reaction [Shih and Lin, 2012; Gramlich et al., 2013] . As step-growth polymerization is less susceptible to oxygen inhibition, it results in more rapidly forming hydrogels with higher degrees of crosslinking. However, swelling ratios still depend on the total macromer content, indicating that substantial network nonidealities still occur [Shih and Lin, 2012] . Photocrosslinking techniques to develop injectable hydrogels for SCI therapy have been limited due to the difficulty of inducing gelation after injection; exposure of the injured spinal cord to radiation and free radicals postinjury also has the potential to induce further inflammation and damage. However, implantation of preformed, preswollen and photocrosslinked HAbased hydrogels after acute SCI resulted in decreased scar formation [Khaing et al., 2011] . Although preformed gels have limitations in their ability to conform to the irregular defect shape, they can be advantageous in that they can be preswollen prior to implantation while incorporating architectures to promote cell infiltration and axon guidance [Prang et al., 2006; Gros et al., 2010; Griffin et al., 2015; Pawar et al., 2015b] .
Nonphotocrosslinking covalent strategies avoid the need for potentially cytotoxic initiators -previously used methods to fabricate injectable hydrogels include 'click' chemistries [Führmann et al., 2015] and enzymatic reactions [Johnson et al., 2010a; King et al., 2010; Teixeira et al., 2012] . The most widely used enzymatic strategies employ thrombin to crosslink fibrin hydrogels, exploiting the natural blood clotting process [Johnson et al., 2010a , Lu et al., 2012 Sharp et al., 2012; Griffin et al., 2015] . Fibrin hydrogels can have linear compressive modulus of <1,000 Pa, similar to native spinal cord tissue, and relatively low swelling ratios (<20%; table 1 ). Nonphoto-induced 'click' reactions (e.g. Diels-Alder type) also proceed by stepgrowth polymerization, enabling more controlled network formation [Hiemstra et al., 2007; Nimmo et al., 2011; Shih and Lin, 2012; Azagarsamy and Anseth, 2013 Führmann et al. [2015] used HA-based hydrogels produced using a nonphoto-induced click chemistry. The authors reported that these hydrogels swelled to 40-60% of their original mass and did not cause any damage to the spinal cord after intrathecal injection and in situ formation. Both the location of the injection and rate of swelling likely affected this favorable outcome. First, the intrathecal site can accommodate larger injection volumes. Second, the swelling rate after hydrogel formation is relatively slow ( ∼ 20% within the first 12 h, an additional 20% over the next 12 h, and a final 20% by 96 h after injection), which translates to lower pressures exerted on the surrounding tissue.
Multiarm PEG macromers end-capped with click reagents have been widely explored as in situ-forming hydrogels. Using this strategy, the network properties (including swelling and mechanics) can be controlled by the molecular weight of the PEG arms and the stoichiometry of click functionalities [Elbert and Hubbell, 2001; Lutolf and Hubbell, 2003; Shikanov et al., 2011; Kim et al., 2016] . Recent reports indicate that increasing numbers of PEG arms (e.g. 4-vs. 8-arm PEG macromers) increases the gelation rate, reduces swelling ratios by ∼ 40%, and improves overall predictability and reproducibility of hydrogel networks [Kim et al., 2016] . This reduction of variability is particularly important for injection into the spinal cord, where a relatively narrow range of mechanical and/or swelling properties may be required to create good apposition to host tissue and prevent swelling-induced damage.
The gelation time is a particularly important consideration for nonphoto-induced crosslinking methods, as crosslinking is initiated upon first contact with the spinal cord environment. This time must be slow enough to firstly not clog the injection needle and, secondly, to allow for sufficient contact with spared spinal cord tissue prior to gelation. However, the gelation time should be fast enough that the hydrogel and any embedded therapeutic agents (e.g. cells, drugs) remain at the local injection site [Tam et al., 2012] . Previous investigations have reported good tissue apposition with gelation times within approximately 30 min [Liang et al., 2013] . However, more work needs to be done to identify optimum gelation times for different in situ-forming, injectable hydrogels. Recently, Kim et al. [2016] demonstrated that faster network formation correlates to decreased swelling ratios in vitro, independently of the total macromer content. However, it remains unclear how the gelation time affects the pressure exerted during swelling in vivo. In general, photocrosslinking strategies permit better user control as hydrogels form only after exposure to an external light source. Thus, photogelation times are often relatively fast (e.g. 30 s to 3 min). In general, faster times are desired in this case to prevent adverse effects from the photoinitiators.
Bioactive Hydrogels
Ultimately, researchers are developing hydrogels that are able to interact with cells of the spinal cord at a biological level to actively promote tissue regeneration. Although synthetic strategies typically provide better control over their physical properties, naturally derived materials (e.g. HA, alginate, agarose, collagen, fibrin) have been widely investigated for their ability to offer a biocompatible, recognizable interface with which host cells can interact. Natural materials derived from the native spinal cord tissue (e.g. HA, laminin and fibrin) can interact directly with cell surface receptors -leveraging biologically encoded signals to induce regeneration. King et al. [2010] compared viscous fibronectin, and collagen I, fibrin, and fibrin/fibronectin hydrogel implants after SCI in rodents and found that, while all gels interfaced well with the spinal cord, fibrin best supported axon extension, with the addition of fibronectin increasing this effect. After injury, a provisional matrix, composed of fibrin and fibronectin, forms as a support scaffold that cells can infiltrate and remodel into repaired tissue. While not abundant in the uninjured spinal cord, a fibrin/fibronectin matrix quickly forms after SCI and may promote wound healing through similar mechanisms as in peripheral tissues. One concern with animal-derived sources of proteins with poorly conserved homology is that the biological response in humans may depend on the source. For example, salmon fibrin has been reported to more effectively support neurite outgrowth and SCI recovery in rodents than bovine or human fibrin [Ju et al., 2007; Sharp et al., 2012] . Hydrogels fabricated from HA, the dominant extracellular matrix (ECM) component in the spinal cord and a polysaccharide with very low interspecies variability, has also shown great promise for SCI treatment. Both covalently [Khaing et al., 2011; Führmann et al., 2015] and physically [Gupta et al., 2006; Austin et al., 2012; Caicco et al., 2013] crosslinked HA hydrogels reduce inflammation and glial scar formation after SCI.
Synthetic hydrogels [e.g. PEG and poly(2-hydroxyethyl methacrylate)] are highly resistant to protein adsorption and generally do not support cell adhesion, providing a 'blank slate' to which adhesive and other bioactive factors can be added with a high degree of user control. Many researchers have conjugated short, cell-adhesive peptides derived from the native ECM to synthetic hydro-gels. Although these short peptide derivatives may have less potent bioactivity than their full proteins of origin, they can still support robust, cell receptor-specific adhesion [Silva et al., 2004; Tysseling-Mattiace et al., 2008; Tam et al., 2012; Lam et al., 2014] . Furthermore, the density and presentation (spatial orientation) of peptides within the hydrogel network can be precisely defined. The most commonly used of these adhesive peptides is the integrin-binding RGD sequence, which is found in many ECM proteins. Such hybrid hydrogels -combining synthetic polymers with naturally derived biomolecules -can provide biologically recognizable cues with a high degree of user control over biomaterial properties.
Recent developments in designer protein or peptidebased hydrogels have attempted to achieve the consistency of purely synthetic hydrogels while retaining beneficial signaling aspects of natural hydrogels. This includes selfassembling or crosslinked polypeptides developed from di-block copolypeptides or elastin-like polypeptides [Wong Po Foo et al., 2009; Yang et al., 2009a; Cai et al., 2014; Wang et al., 2015] . Such hydrogels can easily incorporate a variety of signaling peptide sequences, generally derived from proteins including laminin, fibronectin, or neural cell adhesion molecule (NCAM). For SCI applications, laminin-1-derived peptides, including those containing YIGSR or IKVAV, have shown potential to improve neural cell adhesion and neurite extension. Peptide amphiphiles containing the IKVAV sequence have been synthesized and developed to self-assemble into nanofiber-based hydrogels after injection into the CNS [Silva et al., 2004; Tysseling-Mattiace et al., 2008] . In a rodent model of SCI, IKVAV-containing nanofibers reduced glial scar formation, increased cell survival, and promoted the regeneration of both descending motor and ascending sensory tracts [Tysseling-Mattiace et al., 2008] . In vitro, hydrogels bearing a specific combination of RGD, YIGSR and IKVAV maximized the neuronal differentiation of cultured neural stem cells [Lam et al., 2014] . However, more research is needed to characterize the relative and combinatorial effects of these peptides on regeneration after SCI.
Delivery of Therapeutic Agents
Hydrogels can also be used as delivery vehicles for other therapeutic agents, including proteins, small-molecule drugs, genes and live cell transplants. Swelling or changes in mesh size can have significant effects on: (1) the dynamics of release of bioactive factors from hydrogels, and (2) cell infiltration into hydrogels, which is a prerequisite for effective gene delivery. One strategy is to incorporate chemoattractant and/or neurotrophic growth factors (e.g. glial-derived growth factor, sonic hedgehog, brainderived growth factor, neurotrophin-3) that improve cell survival and actively promote axon migration into the hydrogel implant [Piantino et al., 2006; Johnson et al., 2010b; Lampe et al., 2010; Lowry et al., 2012; Ansorena et al., 2013; Führmann et al., 2015] . The release and bioactivity of these factors is often prolonged through the encapsulation in biodegradable, polymeric microparticles embedded within injectable hydrogels Lowry et al., 2012; Ansorena et al., 2013] . A similar microparticle-based approach has been used to deliver chondroitinase ABC, an enzyme that degrades the glial scar [Wilems and Sakiyama-Elbert, 2015] . Alternatively, the conjugation of heparin, which acts to locally tether growth factors and prolong their release, to fibrin hydrogels has been successfully employed in rodent SCI [Johnson et al., 2010b] . This approach is interesting since the release of the payload is not dependent on the degradation of the hydrogel scaffold, although the diffusion rate is still dependent on the mesh size of the hydrogel. Similarly, chondroitinase ABC has been delivered from methylcellulose hydrogels through affinity release [Pakulska et al., 2013] . Small-molecule drugs, such as the steroid methylprednisolone, can also be delivered via hydrogelembedded microparticles Browne and Pandit, 2015] . In both strategies, swelling directly affects release profiles, where increased water uptake and a larger mesh size result in faster diffusion out of the hydrogel.
Alternatively, genes encoding bioactive proteins can be delivered to the spinal cord using viral and nonviral carriers tethered to hydrogel scaffolds Walthers and Seidlits, 2015] . Gene delivery allows for the continued production of bioactive factors by transduced/transfected cells in situ without repeated invasive administration. For example, the single-dose delivery of chondroitinase ABC-encoding lentivirus after contusive SCI results in significant functional improvement [James et al., 2015] . The delivery of genes encoding other therapeutic biomolecules, such as growth factors and anti-inflammatory cytokines, has also been reported to enhance spinal cord regeneration [Tuinstra et al., 2012; Thomas et al., 2014] . Efficient, biomaterial-mediated delivery of genes is less dependent on hydrogel swelling than the delivery of proteins or other small molecules. Instead, delivery efficiency is dictated by the number of cells that have physically encountered genetic vectors, which is directly affected by the cells' ability to adhere to and migrate through gene-loaded hydrogel implants [Aviles and Shea, 2011; Shepard et al., 2012] . Cell infiltration into hydrogels is directly related to material mesh size and swelling, where a larger mesh size and higher degrees of swelling typically result in increased numbers of infiltrating cells.
Finally, hydrogels can be used as injectable carriers for therapeutic cell transplants, including neural and embryonic stem cells [Lu et al., 2012; Liang et al., 2013; Mothe et al., 2013; Shrestha et al., 2014; Assuncao-Silva et al., 2015] . Alternatively, engineered cells producing specific regenerative factors can be delivered without the need for repeated administration, as would be required for the direct delivery of 'naked' protein [Conova et al., 2011; Bearat et al., 2012] . The same requirements that make hydrogels suitable for in situ gelation -compatibility with aqueous, noncytotoxic chemistries -enable the hydrogel-mediated delivery of live cells, where cells are embedded in the liquid hydrogel precursor prior to injection and in situ crosslinking [Lu et al., 2012; Liang et al., 2013; Mothe et al., 2013] . Although cell transplants have shown exciting potential as a clinical therapy for SCI, low survival rates and inefficient differentiation are major barriers to clinical translation. Evidence of poor survival was recently reported by Sontag et al. [2014] , who reported that approximately 90% of transplanted human oligodendrocyte progenitor cells died either during or immediately after transplantation when suspended in a buffered solution and injected directly into the spinal cord. However, recent reports indicate that delivery within hydrogel carriers with shear-thinning properties -meaning that viscosity decreases with the application of increasing shear stress -act to protect cells from death during injection [Aguado et al., 2011; Liang et al., 2013; Mothe et al., 2013] .
Swelling and mesh size affect the diffusion of nutrients, waste and other bioactive factors through in situformed hydrogels, directly affecting the survival, growth and phenotype of encapsulated cells. There is also some evidence that hydrogels with relatively large swelling pressures can physically 'crush' encapsulated cells, severely limiting their viability [Shikanov et al., 2009] . Dual-network hydrogels may circumvent this risk. For example, cell-mediated degradation of the fibrin component in interpenetrating networks of fibrin and alginate permit encapsulated ovarian follicles to expand in size while the remaining alginate structure maintains mechanical integrity [Shikanov et al., 2009] . Additional bioactive factors can be included to further enhance the therapeutic benefits of cell transplants. For example, adult rodent neural progenitor cells delivered via HAMC hydrogels after SCI improved survival and increased oligodendrocyte-lineage differentiation .
Host-Biomaterial Interface
The successful induction of spinal cord regeneration by hydrogel implants has been limited, at least in part, due to minimal cell infiltration and axon extension into the hydrogels, resulting in poor integration with host tissues [Khaing et al., 2011; Pakulska et al., 2012] . Biomaterials that provide structural support and contain cell-scale macropores can prevent cyst formation and promote ample cell infiltration within the first few days of implantation, allowing a permissive interface between the biomaterial and the host spinal cord tissue [Yang et al., 2009b; Tuinstra et al., 2012; Thomas et al., 2013] . This early integration results in reduced glial scar deposition, which can allow more regenerating axons to enter, cross and exit the injury site via polymeric bridges [Tuinstra et al., 2012 [Tuinstra et al., , 2013a Pawar et al., 2015a] . Macroporosity may also provide an avenue for the rapid revascularization of lesions to further benefit tissue sparing and functional outcomes after SCI. As macroporosity improves the infiltration of host cells through hydrogel implants, the same macroporous architecture can support the migration of transplanted cells into the surrounding tissue and, potentially, their functional integration with the patient's spinal cord. In the case of gene therapies, macroporosity-facilitated cell infiltration can enable more cells to contact genetic vectors, thereby increasing the delivery efficiency [Aviles and Shea, 2011; Shepard et al., 2012; Thomas et al., 2014] . The in situ crosslinking and swelling of hydrogels in irregularly shaped injection sites allows for a more intimate interface with host tissue, where some swelling pressure may actually help keep the implant positioned flush against tissue. As discussed throughout this review, this swelling pressure must be regulated so as not to induce physical injury to the host tissue. Typical injectable scaffolds exhibit microscale pores that are much smaller than a migrating cell. Furthermore, altering this microporosity directly affects hydrogel swelling and other properties, and thus is not an ideal route for independently manipulating cell infiltration ( fig. 4 ) .
A few methods describing strategies to create injectable scaffolds with macroscale pores have been reported using three basic strategies: in situ assembly of preformed hydrogel 'beads' [Jia et al., 2006; Griffin et al., 2015] , macroporous cryogels that return to their original shape after injection [Koshy et al., 2014] , and dual-network hydrogels [Shikanov et al., 2009; Bearat et al., 2012; Shih and Lin, 2012; Pakulska et al., 2015; Schweller and West, 2015] . Dual-network hydrogels can be designed so that one network component degrades to create a porous structure while the other remains intact to preserve mechanical integrity and control hydrogel swelling [Shikanov et al., 2009; Schweller and West, 2015] . Alternatively, each network component may be used to independently control material properties, including swelling, mesh size and mechanics [Shih and Lin, 2012] . Griffin et al. [2015] recently demonstrated the assembly of PEG hydrogel beads into a crosslinked biomaterial scaffold using a method based on the fibrin clotting process to yield injectable scaffolds with independent control of mechanics and macroporosity. Like other macroporous, biomimetic scaffolds, these scaffolds improved cell infiltration and integration with host tissue. In addition, the swelling of preformed hydrogel beads to physiological equilibrium prior to in vivo injection may be advantageous over the crosslinking hydrogels in situ, since any potential issues with swelling pressure increasing intraspinal edema are avoided.
Conclusions
Injectable hydrogels are a highly versatile group of biomaterials and their application as SCI therapeutics has gained popularity among a myriad of materials being considered due to their relatively noninvasive administration, biocompatibility, high water content, tissue-like mechanical properties and the ability to deliver regenerative factors, including proteins, small molecules and even living cells. Recent findings in the acute physiology of the spinal cord showed that dramatic increases in intraspinal pressure occur after a traumatic injury, and clinical data suggest that this increase in local tissue pressure is a likely contributor to the progression of secondary injury. In light of these findings, future studies will require the monitoring of changes in intraspinal pressure that may occur during the injection (precrosslinking) and swelling (postcrosslinking) of hydrogel therapeutics. Swelling characteristics of a material can affect delivery specifications, local tissue pressure, apposition to host tissue, and the rate of diffusion of the payload from the material, and therefore have significant bearings on the success of biomaterial-based therapeutics in vivo. Although excessive hydrogel swelling may cause increased secondary damage when injected into restricted sites, such as the parenchyma, hydrogels placed at subdural sites that can absorb excess fluid from the cord after acute SCI may represent a unique opportunity for injectable biomaterials that positively affect functional recovery. As SCI repair is a highly complex process that will likely require combinatorial approaches to address clinically, it is crucial for researchers to continue developing improved hydrogel fabrication strategies to achieve better control over swelling in a manner that is decoupled from other properties with major effects on the physiological response, including mechanics, macromer content and permeability. 
